Rivus Pharmaceuticals, Inc.
HU6
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Countdown
236days
Phase 2 readout · ~ Feb 28, 2027 estimated
What's at stake
Phase 2 trial results for HU6 in MASH - Metabolic Dysfunction-Associated Steatohepatitis are due ~ Feb 28, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT07491458: Phase 2 trial, sponsor Rivus Pharmaceuticals, Inc., drug HU6. Primary completion date 2027-02 (estimated).”